Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 3/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16065180 | 0.83 | ERN1 (0.45) | GSK3BCDC7DBF4ALDH1A1HPGD | |
| SCHEMBL16065117 | 0.83 | BCHE (0.40) | TDP1 | |
| SCHEMBL16065184 | 0.80 | CDK5 (0.39) | GSK3BCDK5CDK5R1CDC7DBF4 | |
| SCHEMBL1724832 | 0.80 | CDC7 (0.53) | CDK5CDK5R1CDC7DBF4ALDH1A1 | |
| SCHEMBL16065181 | 0.79 | MAPT (0.42) | GSK3BALDH1A1L3MBTL1 | |
| SCHEMBL16065077 | 0.76 | CYP1A2 (0.46) | GSK3BCDC7DBF4ALDH1A1L3MBTL1 | |
| SCHEMBL17406994 | 0.76 | IRAK4 (0.38) | GSK3BCDC7DBF4 | |
| SCHEMBL939732 | 0.74 | ALDH1A1 (0.52) | CDK5CDK5R1CDC7DBF4ALDH1A1 | |
| SCHEMBL17407105 | 0.73 | NPC1 (0.37) | ALDH1A1JMJD6PIK3CA | |
| SCHEMBL16065225 | 0.71 | HPGDS (0.49) | CDK5CDK5R1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970334-B1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014143672-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN IDEC MA INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK4, IRAK1, IRAK2 | GSK3B 1207/4885CDK5 392/4885CDK5R1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.